[srp post_limit=”1″ widget_title=”” thumbnail_height=”300″ thumbnail_width=”300″ wp_thumbnail_size=”medium” ext_shortcodes_compatibility=”yes” post_content_length=”” post_content_length_mode=”” post_content_type=”” post_title_length_mode=”words” string_break=”” title_string_break=”” post_author_url=”no” post_category_link=”no” widget_title_hide=”yes” post_title_header=”h3″]

Senior Research Associate

The Person and Role We are seeking highly-motivated and talented senior research associate to join our Assay Development team. Successful applicants will possess strong molecular biology skills and a demonstrated

Read More »

Aldatu Biosciences Expands PANDAA Platform Beyond HIV with SBIR for the First Pan-Lineage Lassa Fever Test

Aldatu Biosciences, a biotechnology company developing molecular diagnostic assays and products based on gold standard real-time PCR, today announced it has been awarded a $300K Phase I SBIR grant from the NIAID at the NIH to fund the continued advancement of the company’s proprietary PANDAA™ technology platform and its specific application to the universal, pan-lineage detection of Lassa virus, the causative agent of Lassa fever.

Read More »

In Memory of Mark Wainberg: Aldatu Advisor and HIV Pioneer

It is with deep sadness that we pass along news of the sudden death of our friend, mentor, and Scientific Advisory Board member, Prof. Mark Wainberg. Mark was one of the earliest supporters of Aldatu and our efforts to bring PANDAA to patients, and for that he will always have our gratitude. His passing represents a tremendous loss for not only our company, but the entire HIV community. Our hearts and thoughts are with his family and colleagues today.

Read More »
Life Lab grand opening

Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic Development

Aldatu Biosciences has been awarded a Direct-to-Phase II Small Business Innovation Research (SBIR) grant for approximately $3,000,000 over three years from the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health (NIH). The award will fund the continued advancement of the company’s proprietary platform technology, PANDAA, and its specific application to HIV genotyping.

Read More »